MARKET ACCESS INTELLIGENCE • Weekly Digest • April 24, 2026

TOP STORIES

340B AstraZeneca joins the manufacturer counter-offensive as Washington State becomes the newest 340B litigation front

AstraZeneca filed the fourth manufacturer lawsuit challenging Washington State's recently enacted contract pharmacy access law, according to 340B Report's coverage. Washington's statute prohibits drugmakers from restricting 340B-priced products from being dispensed through contract pharmacy arrangements, joining a growing patchwork of state laws that have moved into the regulatory vacuum left by federal uncertainty over the 340B rebate model. Three other manufacturers had already filed parallel challenges, and the AstraZeneca complaint mirrors their core arguments: federal preemption, violation of the Takings Clause, and structural incompatibility with HHS's Section 340B statutory framework. Washington now sits alongside Hawaii, Colorado, Vermont, and Oklahoma as states whose contract pharmacy protections face active manufacturer litigation, with additional bills progressing in at least half a dozen other state legislatures.

Competitive implications: For AstraZeneca, Eli Lilly, Novartis, and Sanofi—the most active manufacturer litigants—each state-level victory preserves existing contract pharmacy restriction models but at growing reputational and legal cost, with each new suit amplifying the "manufacturer-vs-safety-net" framing that dominates public coverage. Safety-net hospitals and FQHCs in Washington retain protected contract pharmacy access pending the court's injunction ruling. Walgreens, CVS, Walmart, and the Big Three PBM-owned contract pharmacy networks—which together hold roughly 73% of the 160,000 contract pharmacy relationships nationally—retain revenue flows in Washington regardless of the eventual legal outcome.

Policy FTC moves against deceptive health plan marketing scheme targeting individual-market shoppers

A U.S. district court in Florida granted the Federal Trade Commission's request for a temporary restraining order against a nationwide operation that allegedly impersonated the federal government and major insurance carriers to deceive consumers into purchasing sham PPO plans. The complaint alleges the scheme marketed supposedly comprehensive coverage using fake government seals and insurer logos, while the underlying products offered none of the benefits represented to buyers. The action represents one of the largest consumer-protection cases in the health-insurance space since the FTC's 2023 enforcement push against non-compete clauses and arrives as the same agency continues to scrutinize vertical integration among the Big Three PBMs and their affiliated insurers.

Policy PCMA's "insider's guide" previews the PBM industry's 2027 legislative posture—symmetric transparency is the next ask

The Pharmaceutical Care Management Association—the trade group representing the largest PBMs—published an insider's guide to newly enacted PBM reform, framing the CAA 2026 as the transformation that makes PBMs "the most transparent actor in the prescription drug supply chain." The guide emphasizes that the law requires PBMs to fully disclose all forms of compensation in Medicare Part D and argues, by extension, that manufacturer list-price decisions and wholesaler distribution fees now warrant equivalent transparency mandates. PCMA's framing notably reframes the reform as a competitive reset rather than a structural rebuke—a positioning that will matter as the 2028 effective date approaches and PBMs push for symmetric transparency obligations elsewhere in the supply chain.

FORMULARY & BIOSIMILARS

• Formulary Drug Channels guest post from Laura Jensen (GoodRx Pharma Direct) argues that manufacturers must move beyond payer-centric commercial models toward integrated platforms combining direct-to-consumer, employer, and cash-pay channels—a thesis that gains commercial urgency as CAA 2026 reshuffles rebate-driven formulary placement predictability for specialty brands.
• Formulary Mark Cuban told FierceHealthcare that Congress should "not be a wimp" about breaking up vertically integrated PBMs, arguing that combined PBM, payer, and specialty-pharmacy ownership prevents efficient drug-market pricing. The comments amplify mounting political pressure for structural rather than transparency-only PBM reform at a time when the FTC's consolidation review remains active.
• Formulary AMCP's legislative update on the Alternatives to Prevent Addiction in the Nation (PAIN) Act flags bipartisan reintroduction of the bill, which would require Medicare Part D plans to cover non-opioid pain management therapies. Formulary implications are material for branded non-opioid pain products if coverage mandates advance, particularly in step-therapy designs.
• Formulary CMS and FDA announced the RAPID Coverage Pathway to accelerate Medicare coverage for FDA-designated breakthrough medical devices. Though focused on devices rather than drugs, the precedent of paired FDA–CMS acceleration is notable—it mirrors the structure market access advocates have long sought for breakthrough drug therapies and cell/gene therapies.

PRICING & REIMBURSEMENT

• Pricing Adam Fein's annual Top 15 Specialty Pharmacies analysis confirms that PBM-affiliated specialty pharmacies continued to dominate 2025 dispensing, while health-system and independent specialty pharmacies made relative share gains. The analysis sharpens the case for scrutiny of PBM specialty-channel integration as CAA 2026 disclosure requirements take effect in 2028.
• Pricing STAT News reports that CMS and FDA are jointly proposing the new RAPID Medicare coverage pathway for breakthrough devices—the same framework flagged in the Formulary section, here analyzed from the reimbursement-timing perspective. Drug-side market access teams should monitor whether the framework precedent migrates toward ATMPs and breakthrough-designated therapeutics in subsequent rulemaking cycles.
• Pricing Regeneron announced a drug-pricing deal with the White House, becoming the 17th and final manufacturer from the administration's initial MFN target list to reach agreement. Full terms have not been disclosed, but the sequential capitulation removes a key counter-narrative for manufacturers still resisting state-level reference pricing initiatives and strengthens the administration's hand in Cycle 2 IRA negotiation.

POLICY & REGULATORY

• 340B Dueling congressional letters on the 340B rebate model have emerged: two GOP House lawmakers circulated support for rebate architectures, while eight Senate Democrats joined a separate effort opposing them. The split is not strictly partisan but confirms that 340B rebate structure is now a live bipartisan fight heading into the 2026 midterm cycle.
• Policy AMCP's update on the Patients Deserve Price Tags Act (S. 2355 / H.R. 5582) notes a Senate hearing this month on price transparency requirements for providers and facilities. The bill's direct formulary relevance is limited, but it reflects the broader regulatory posture favoring disclosure-based reforms over direct price controls.
• Policy PCMA argues that the Department of Labor's proposed rule on PBM fee disclosure is now duplicative with CAA 2026 provisions and should be withdrawn. The DOL–HHS jurisdictional question is genuine: CAA 2026 assigns enforcement authority for PBM transparency to both agencies, with overlapping employer-plan requirements creating compliance ambiguity.

WHAT TO WATCH NEXT

HRSA "Gang of Six" briefing on 340B rebate model—policy direction remains unsettled at HHS

HHS Secretary Kennedy's Senate testimony that he does not know the current status of the 340B Rebate Model and will direct HRSA to brief the bipartisan "Gang of Six" is notable less for the substantive knowledge gap than for signaling that 340B policy direction at HHS remains actively unresolved following February's federal court vacatur. Expect HRSA to release either a revised rulemaking framework or a synthesis of its April 20 RFI responses by mid-Q3 2026. Manufacturers should continue scenario planning for both rebate and upfront-discount architectures through year-end, and covered entities should treat the summer rulemaking window as the highest-leverage comment opportunity of the 2026 cycle.

Minnesota 340B analysis—uncompensated-care framing faces mounting empirical pressure

Drug Channels' new Minnesota 340B analysis showing that the state's 340B hospitals earn roughly $1 billion more from 340B program revenue than they spend on uncompensated care extends a research line that challenges the hospital-sector framing of 340B as a charity-care funding stream. Expect the analysis to be cited prominently in HRSA RFI response submissions and, likely, in the administration's 2027 budget proposal for 340B restructuring. For manufacturers, the report strengthens the empirical case for the rebate model; for safety-net hospitals, it accelerates the need to publish institution-level 340B revenue-use transparency data pre-emptively.

HHS, TrumpRx, and PBM policy alignment—implementation consensus not yet in place

PharmaVoice's reporting on tensions between HHS leadership and industry at a recent policy forum—including on-stage exchanges involving Dr. Oz, Mark Cuban, and PhRMA's Stephen Ubl—signals that implementation of TrumpRx and the MFN framework is not yet consensus-aligned within HHS. Watch for a CMS policy paper or RFI in Q2 that formalizes the TrumpRx channel architecture and its interaction with Medicare Part D. Manufacturers with MFN agreements in place should begin scenario modeling for TrumpRx channel participation terms, since channel architecture choices made in 2026 will propagate through commercial, specialty, and 340B contracting for the remainder of the administration.